Sitemap
Posts
- Category: Erectile Dysfunction
- Category: Healthcare
- Category: Icon Bioscience
- Icon Bioscience Achieves Key Milestone with IBI-10090 Advancing Through Phase 3 Studies
- Icon Bioscience Announces David S. Tierney, MD Joined the Company as President & Chief Executive Officer
- Icon Bioscience Announces Early Completion of Patient Enrollment in its Phase 3 Study of IBI-10090; Drug Addresses Market Need for Long-Acting Treatment of Inflammation Post Cataract Surgery
- ICON BIOSCIENCE ANNOUNCES FDA ACCEPTANCE OF NDA FILING FOR DEXYCU, A NOVAL DRUG THERAPY FOR TREATING INFLAMMATION ASSOCIATED WITH CATARACT SURGERY
- Icon Bioscience Announces Pivotal Phase 3 Clinical Data Demonstrates Exceptional Efficacy of IBI-10090 in Reducing Inflammation Associated With Cataract Surgery
- Icon Bioscience Reports Last Patient Out in its Phase 3 Study Of IBI-10090
- Icon Bioscience Reports Successful Outcomes Of Phase 3 Study Of Ibi-10090, A Novel Sustained Release Drug Being Developed To Treat Inflammation Associated With Cataract Surgery
- Icon Bioscience Submits NDA For DEXYCU, A Potential Transformational Drug Therapy For Treating Inflammation Associated With Cataract Surgery
- Icon Bioscience’s Founder Honored by Foundation Fighting Blindness
- Icon’s Melphalan Intraocular Injection Granted U.S. Orphan Drug Status Designation for the Treatment of Retinoblastoma
Pages
- About
- About Us
- About Us
- American Academy of Ophthalmology (AAO)
- Careers
- Clinical Background
- Contact Us
- European Society of Cataract and Refractive Surgeons (ESCRS)
- Events
- FAQ
- Follow-On Products
- IBI-10090
- IBI-10090
- IBI-20089
- IBI-60089
- IBI-80090
- Icon Bioscience Achieves Key Milestone with IBI-10900 Advancing Through Phase 3 Studies; Drug Targets Medical Need for Long-Acting Treatment of Inflammation Post Cataract Surgery
- Icon Bioscience Announces Daniel Dale, M.D. Joined The Company As President & Chief Executive Officer
- Icon Bioscience Announces Early Completion of Patient Enrollment in its Phase 3 Study of IBI-10090; Drug Addresses Market Need for Long-Acting Treatment of Inflammation Post Cataract Surgery
- Icon Bioscience’s Founder & Chairman, Vernon G. Wong MD, Honored by Foundation Fighting Blindness
- Icon’s Melphalan Intraocular Injection Granted U.S. Orphan Drug Status Designation for the Treatment of Retinoblastoma
- Immunization
- Intellectual Property
- My Canadian Pharmacy: Generic Vendor with Quality Drugs
- News
- News & Events
- Ophthalmic Markets
- Overview
- Partnering
- Pipeline
- Prescriptions
- Privacy Policy
- Products
- Refill
- Services
- Sitemap
- Specialty Care
- Staff
- Terms of Use
- Transfer RX
- Verisome®
- Verisome® Drug Delivery Technology